Probiodrug Ag

Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.v.

Vivoryon Therapeutics N.v.

Vivoryon Therapeutics Ag

Mirko Buchholz

Ulrich Heiser

Hans-Ulrich Demuth

Andre Johannes Niestroj

Stephan Schilling

Daniel Ramsbeck

Michael Thormann

Andreas Treml

Robert Sommer

Michael Altmstetter

Torsten Hoffmann

Dagmar Schlenzig

André Johannes Niestroj

Jens-Ulrich Rahfeld

Holger Cynis

Antje Meyer

Livia Boehme

Michael Wermann

Anke Piechotta

Antje Hamann

Torsten Hoffman

Jan Potempa

Sigrun Eick

Nadine Taudte

Stephen Schilling

Antje Harmann

Diane Meitzner

Stefanie Geissler

Miriam Linnert

Linda Liebe

Christian Jäger

The present invention relates to novel hydroxamic acid derivatives as inhibitors of meprin β and/or α, pharmaceutical compositions comprising such compounds, methods for treatment or prophylaxis of diseases or conditions, especially such that are related to meprin β and/or α, and compounds and pharmaceutical compositions for use in such methods.

Inhibitors of meprin α and β

The present invention relates to novel compounds which are particularly useful as inhibitors of bacterial glutaminyl cyclases (bacQC); pharmaceutical compositions comprising such compounds; compounds and/or pharmaceutical compositions for use in methods for treatment, in particular for use in the treatment of periodontitis and related conditions; as well as to crystals comprising bacterial glutaminyl cyclases, methods for identifying candidate compounds which may associate with the binding pocket of a bacQC and/or are bacQC inhibitors.

Inhibitors of bacterial glutaminyl cyclases for use in the treatment of periodontal and related diseases

The present invention relates to bacterial glutaminyl cyclases and inhibitors thereof for use in the treatment of periodontitis and related conditions, and provides a bacterial glutaminyl cyclase (bacQC); an antibody which recognizes the bacQC, a method for identifying an inhibitor of the bacQC; a compound according to Formula (I); a pharmaceutical composition comprising a bacQC inhibitor compound; a bacQC inhibitor compound and/or a pharmaceutical composition for use in a method for treatment of the human or animal body, for use in a method for therapy or prophylaxis of a bacterial infection, and for use in a method for therapy and/or prophylaxis of an acute, chronic or recurrent periodontal disease.

Bacterial glutaminyl cyclases and inhibitors thereof for use in the treatment of periodontitis

The present invention relates to novel hydroxamic acid derivatives as inhibitors of meprin &#x3b2; and/or &#x3b1;, pharmaceutical compositions comprising such compounds, methods for treatment or prophylaxis of diseases or conditions, especially such that are related to meprin &#x3b2; and/or &#x3b1;, and compounds and pharmaceutical compositions for use in such methods.

Inhibitors of meprin &#x3b1; and &#x3b2;

Compounds of formula (I), combinations and uses thereof for disease therapy, or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein: 

Inhibitors of glutaminyl cyclase

The invention relates to a compound of formula (I) or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof, wherein R, R, R, Rand Rare as defined herein, as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water. 

Inhibitors

Compounds of formula (I), combinations and uses thereof for disease therapy,  

The present invention relates to compounds of formula (I), combinations and uses thereof for disease therapy, wherein

Provided herein are methods for treating and preventing neurodegenerative disease in a mammal by administering an inhibitor of glutaminyl cyclase (QC). Neurodegenerative diseases treatable or preventable according to methods described herein include mild cognitive impairment (MCI), Alzheimer's disease, neurodegeneration in Down Syndrome, Familial British Dementia, and Familial Danish Dementia.

Method for prophylactic treatment of alzheimer's disease using inhibitors of glutaminyl cyclase and glutamate cyclases

Compounds of formula (I), combinations and uses thereof for disease therapy, or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers, stereoisomers and polymorphs thereof, wherein A, B and Rare as defined throughout the description and the claims.

The present invention relates to compounds of formula (I), combinations and uses thereof for disease therapy, or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein

The present invention relates to compounds of formula (I), combinations and uses thereof for disease therapy, 

Compounds of formula (I), combinations and uses thereof for disease therapy, or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein: and R, B and Y are as described throughout the description and the claims.

Growing community of inventors

Halle/Saale, Germany

Mirko Buchholz